Rodriguez-Cruz J Jesus, Chapa-Villarreal Fabiola A, Duggal Ishaan, Peppas Nicholas A
Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA.
McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA.
J Control Release. 2025 Aug 10;384:113940. doi: 10.1016/j.jconrel.2025.113940. Epub 2025 Jun 6.
Scientific and industrial interest in the controlled delivery of biologics has sparked unparalleled growth in the development of new treatment technologies for a variety of diseases. However, due to the highly unstable nature of biologics in physiological conditions, there is a critical need for carriers that can prevent their degradation, target their delivery, and increase their half-lives after administration. Polymeric nanoparticles have emerged as superior drug vehicles due to their versatility and biocompatibility which earns them significant potential to safely and efficiently deliver therapeutics to different parts of the body. Similarly, the rational design of the polymer nanoparticles can optimize their performance as biologic delivery carriers and enable a variety of advanced functions such as specific targeting, stealth properties and sustained release among others. However, to achieve the clinical translation of such systems, their optimal design requires careful consideration of materials, safe synthesis and fabrication methodologies, large-scale manufacturing potential, and a good measure of efficacy via in vitro or in vivo studies. In this detailed and critical analysis, we summarize the most recent work on a variety of polymer nanotechnologies to achieve improved delivery of biologics, highlighting the critical roles of layer-by-layer nanoparticles, dendrimers, nanogels, self-assembled nanoparticles, nanocomplexes, and nanoparticle hybrids. We provide an overview of key clinical translation considerations for these products to reach the clinic. Finally, we discuss the remaining challenges in the delivery of biologics and offer an outlook onto the future development of these technologies.
对生物制剂控释的科学及产业兴趣引发了针对多种疾病的新型治疗技术开发的空前增长。然而,由于生物制剂在生理条件下高度不稳定的性质,迫切需要能够防止其降解、靶向递送并延长其给药后半衰期的载体。聚合物纳米颗粒因其多功能性和生物相容性而成为优异的药物载体,这使其具有将治疗剂安全有效地递送至身体不同部位的巨大潜力。同样,聚合物纳米颗粒的合理设计可以优化其作为生物制剂递送载体的性能,并实现多种先进功能,如特异性靶向、隐身特性和持续释放等。然而,要实现此类系统的临床转化,其优化设计需要仔细考虑材料、安全的合成及制造方法、大规模生产潜力,以及通过体外或体内研究对疗效进行的充分评估。在这一详细且关键的分析中,我们总结了关于多种聚合物纳米技术以实现生物制剂更好递送的最新研究工作,突出了层层组装纳米颗粒、树枝状聚合物、纳米凝胶、自组装纳米颗粒、纳米复合物和纳米颗粒杂化物的关键作用。我们概述了这些产品进入临床所需考虑的关键临床转化因素。最后,我们讨论了生物制剂递送中仍然存在的挑战,并展望了这些技术的未来发展。